Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Busulfan Dose Escalation in HCT Conditioning
NCT00361140Phase 4Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2005
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of busulfan in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL) and 6 more (3 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Non-relapse Mortality at 100 days. Started Aug 2005; status: completed.
02
Drugs
busulfan
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)myelodysplastic syndrome (MDS)chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00361140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361140.